
Colorectal Cancer
Latest News

Latest Videos

Shorts

Podcasts
CME Content
More News

FDA-approved colorectal cancer blood tests—Shield, Epi proColon, SimpleScreen—expand blood-based screening, but positives still need colonoscopy.

The FDA approved SimpleScreen CRC, a blood-based screening test for average-risk adults aged 45 and older, potentially expanding screening access.

ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.

Neoadjuvant pembrolizumab in colorectal cancer delivers durable, relapse-free outcomes presurgery, with ctDNA blood tests helping to predict responders.

AACR data show tumor molecular profiling finds actionable PIK3CA in breast and colorectal cancer, while ctDNA adds real-time monitoring in oncology.


FDA approves encorafenib plus cetuximab chemotherapy for BRAF V600E metastatic colorectal cancer, boosting survival and response in BREAKWATER.

Elicio Therapeutics' ELI-002 2P cancer vaccine shows promising survival benefits in patients with pancreatic and colorectal cancer, enhancing immune responses.

Y-90 resin microspheres offer a new option for patients with liver cancer for the treatment of unresectable hepatocellular carcinoma.

High LDL Cholesterol Associated With Earlier Progression in Synchronous Metastatic Colorectal Cancer
In patients with synchronous metastatic colorectal cancer treated without curative intent, high low-density lipoprotein (LDL) cholesterol was associated with poor survival.

Acneiform rash is a common adverse effect of EGFR-targeting therapies.

A phase 2 trial showed that using ctDNA to guide adjuvant pembrolizumab therapy after surgery effectively cleared minimal residual disease and reduced recurrence in patients with resected mismatch repair-deficient (dMMR) solid tumors.

The study found that 4 weeks was the ideal time point to test for cTDNA.

NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy.


The approval was based on efficacy and safety data from a randomized, 3-arm, open-label phase 3 CHECKMATE-8HW trial.

Using central obesity measures provides more accurate estimates of the proportion of CRC cases attributable to excess weight compared to using BMI alone.

Encorafenib in combination with cetuximab and mFOLFOX6 met its dual primary end point of overall response rate of 61%.

Nivolumab plus ipilimumab demonstrated a 38% reduction in the risk of disease progression or death.

Data from the CodeBreaK 300 trial supported the FDA's approval.

Pharmacists play a vital role in cancer prevention and early detection by educating patients on risk factors, counseling on screening guidelines, and promoting adherence to evidence-based recommendations for common cancers, such as breast, cervical, colorectal, lung, prostate, and skin cancer.














































































































